[go: up one dir, main page]

DK3018132T3 - Kondenserede imidazolderivater anvendt som ido-inhibitorer - Google Patents

Kondenserede imidazolderivater anvendt som ido-inhibitorer Download PDF

Info

Publication number
DK3018132T3
DK3018132T3 DK15197593.5T DK15197593T DK3018132T3 DK 3018132 T3 DK3018132 T3 DK 3018132T3 DK 15197593 T DK15197593 T DK 15197593T DK 3018132 T3 DK3018132 T3 DK 3018132T3
Authority
DK
Denmark
Prior art keywords
imidazo
isoindol
ethyl
hydroxy
cyclohexyl
Prior art date
Application number
DK15197593.5T
Other languages
English (en)
Inventor
Mario Mautino
Jesse Waldo
Firoz Jaipuri
Xiaoxia Zhang
Sanjeev Kumar
Tanay Kesharwani
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Application granted granted Critical
Publication of DK3018132T3 publication Critical patent/DK3018132T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (14)

1. Farmaceutisk sammensætning, der omfatter en forbindelse, der er 2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; ethyl 2-(5H-imidazo[5,1 -a]isoindol-5-yl)acetat; (E)-5-(2-bromstyryl)-5H-imidazo[5,l-a]isoindol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanon; 2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl2-(((lR,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)a cetat; tert-butyl (4-(2-(5H-imidazo[5,1 -a]isoindol-5-yl)acetyl)phenyl)carbamat; 1- (4-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanon; tert-butyl (4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)phenyl)carbamat; 1 -(4-aminophenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5 -yl)-1 -(3 -nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(3-nitrophenyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanol; tert-butyl (2-(2-(5H-imidazo[5,l-a]isoindol-5-yl)acetyl)phenyl)carbamat; tert-butyl (2-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)carbamat; 1 -(2-aminophenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanon; 1- (2-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(2-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanon; 1 -(5H-imidazo[5,1 -a]isoindol-5-yl)-2-methylpropan-2-ol; 1 -(2-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -(3 -chlorphenyl)-2 -(5 H-imidazo [5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-phenylethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -phenylethanol; 1- (2,4-dimethylfuran-3-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(3-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanon; 1 -cyclohexyl-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanon; 1 -cyclohexyl-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-4-yl)ethanol; 2-(7-chlor-5H-imidazo [5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; (Z)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanonoxim; l-cyclopentyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; tert-butyl4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanamin; tert-butyl (3 -(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)phenyl)carbamat; 1- (3-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 4- (2-(6-fluor-5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -hydroxyethyl)cyclohexanol; 1 -cyclohexyl-2-(9-methoxy-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 5- (2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-9-ol; 2- (8-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 1 -(cyclohex-1 -en-1 -yl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1- cyclohexyl-2-(8-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-l -(1,4-dioxaspiro[4.5]decan-8-yl)ethanol; 4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanon; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylencyclohexyl)ethanol; 1 -(cyclohex-3-en-l -yl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1- (4.(hydroxymethyl)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)(thiophen-2-yl)methano n; 1 _(4_( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)ethanon; 2- (5 H-imidazo [5,1 -a]isoindol-5-yl)-1 -(4-methylencyclohexyl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-5-yl)ethanol; 1 .(4-( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2,2-dimethylpropan- 1- on; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(furan-2-yl)ethanol; (1 S)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (lR)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(iodomethylen)cyclohexyl)ethanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)propan-1 -ol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)acetonitril; l-cyclohexyl-3-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)propan-2-ol; 1 -cyclohexyl-3 -(5H-imidazo [5,1 -a]isoindol-5 -yl)propan-2-ol; 1-(4-( 1-hydroxy-2-(5H-imidazo [5,1-a]isoindol-5-yl)ethyl)piperidin-1-yl)-2-phenylethanon; 1 -(4,4-difluorcyclohexyl)-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1- (4,4-difluorcyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-l -(1 -methyl-1 H-imidazol-5-yl)ethanol; 1- (4-(cyclopropylmethylen)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(propan-2-yliden)cyclohexyl)ethanol; (E)-5-(2-cyclohexylvinyl)-5H-imidazo[5,l-a]isoindol; 2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; l-(cyclohex-3-en-l-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (S)-l-cyclohexyl-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (R)-1 -cyclohexyl-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (R) -l-cyclohexyl-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (S) -1 -cyclohexyl-2-((S)-5H-imidazo [5,1 -a]isoindol-5-yl)ethanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yliden)etanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethylacetat; l-(4-(2-(benzyloxy)ethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- (l-(benzylsulfonyl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 _(4_( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(pyrimidin-5-yl)eth anon; 2- (3,4-difluorphenyl)-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl) ethanon; cyclohexyl(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)methanon; methyl 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylat; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylphenylcarbamat; 4-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethoxy)-4-oxosmørsyre; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylbenzoat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(2-(methylsulfonamido)ethyl)cycloh exancarboxamid; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl-2-amino-3-methylbutanoat; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyldihydrogenphosphat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylsyre; 1 _(4_( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(pyridin-4-yl)ethan on; 2-(5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(spiro [2.5 ]octan-6-yl)ethanol; 2- (4-fluorphenyl)-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)etha non; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl 2-aminopropanoat; l-(4.(2-hydroxyethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylpyrrolidin-2-carboxylat; (2S)-5-( 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl) 1 -methyl 2-aminopentandioat; l-(4_((S)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-phenyletha non; (3-fluor-2-hydroxyphenyl)(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-1 -yl)methanon; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxamid; (4-fluorphenyl)(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)methano n; (2S)-2-amino-l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-3-phen ylpropan-l-on; (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)((S)-pyrrolidin-2-yl)met hanon; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl benzoat; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; l-(3-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)azetidin-l-yl)-2-phenylethanon; 3- (1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenyiazetidin-1 -carboxamid; tert-butyl 3 -(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)azetidin-1 -carboxylate l-(azetidin-3-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; tert-butyl 4- ((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxylat; l-((ls,4s)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-3-yl)ethanol; (lr,4r)-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 4-((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxa mid; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboxam id; 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; (lR,4s)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4s)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lS,4r)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4r)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(tetrahydro-2H-pyran-4-yl)ethanon; 1 -(4-((R)-1 -hydroxy-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l -yl)-2-phenyletha non; N-((ls,4s)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; 1 -(4-((S)-l -hydroxy-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -(phenylcarbamoyl)piperidin-4-yl)ethylphenylcarbama t; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4R)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)p iperidin-1 -carboxamid; 4-((S)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4S)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; l-((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- ((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(tetrahydro -2H-pyran-4-yl)ethanon; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-2-yl)ethanol; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-1 -carboxamid; N-cyclohexyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carbo xamid; N-((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; N-cyclopentyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carb oxamid; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(trifluormethyl)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(trifluormethyl)cyclohexyl)ethanol; 1 .(4_((R). i -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(4-(trifluor methyl)phenyl)ethanon; 4-((^)-l-hydroxy-2-((S)-5//-imidazo[5,l-a]isoindol-5-yl)ethyl)-/V-(4-(trifluormethyl)phenyl)pi peridin-1 -carboxamid; (4-((R)~ 1 -hydroxy-2-((S)-5//-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)( 1 H-imidazol-1 -yl)methanon; 1- (5H-imidazo[5,l-a]isoindol-5-yl)-3-methylbutan-2-ol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-3-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(piperidin-3-yl)ethanol; l-cyclohexyl-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; l-cyclohexyl-3-(5H-imidazo[5,l-a]isoindol-5-yl)propan-l-ol; 1- cyclohexyl-2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)-2-(tetrahydro-2H-pyran-4-y l)acetamid; 2- (5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(1 H-imidazol-2-yl)ethanol; 2-(5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(1 H-imidazol-4-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(thiazol-2-yl)ethanol; (5S)-5-(2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-6-ol; l-(2-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)acetamid; N-(2-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)acetamid; 1- cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)-N-methylethanamin; 2- ((l-cyclohexyl-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)amino)ethansulfonamid; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(l-methylpiperidin-4-yl)ethanol; l.(4.aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)cthyl)cyclohexyl)acetamid; l-(4-(aminomethyl)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxamid; 1- (3-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyridin-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyridin-3-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-(pyridin-4-ylmethoxy)cyclohexyl)ethanol; 1 -((lr,4r)-4-((2-aminopyridin-4-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)et hanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyrazin-2-ylmethoxy)cyclohexyl)ethanol; 2- (5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -((1 r,4r)-4-(pyrimidin-5 -ylmethoxy)cyclohexyl)ethanol; l-((lr,4r)-4-((6-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((6-aminopyridin-3-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((3-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((2-aminopyrimidin-5-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl) ethanol; l-((lr,4r)-4-((4-aminopyrimidin-5-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl) ethanol; l-((lr,4r)-4-((5-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; 4-(((( 1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 3- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; methyl 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-methoxycyclohexyl)ethanol; 1- ((lr,4r)-4-ethoxycyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-isopropoxycyclohexyl)ethanol; l-((lr,4r)-4-(cyclopropylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- ((lr,4r)-4-(cyclopentylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(thiophen-2-ylmethoxy)cyclohexyl)ethanol; 1 -((1 r,4r)-4-(( 1 H-indol-3 -yl)oxy)cyclohexyl)-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethanol; 1 -((1 r,4r)-4-(( 1 H-indol-5 -yl)oxy)cyclohexyl)-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-((tetrahydro-2H-pyran-4-yl)methoxy)cyclohexyl)etha nol; 4-(((4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)benzensulf onamid; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(oxazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(thiazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -(1 -imino-2-phenylethyl)piperidin-4-yl)ethanol; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboximidamid; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(pyridin-4-yl)piperidin-1 -carboximi damid; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)piperidin -1 -carboximidamid; N-(4-cyanophenyl)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxa mid; N-(tert-butyl)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxamid; N-(tert-butyl)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-sulfonamid; 1 _(4_( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l -yl)-2-(3-hydroxyphenyl) ethanon; 2-(1 -(azetidin-1 -carbonyl)piperidin-4-yl)-2-hydroxy-1 -(4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoi ndol-5 -yl)ethyl)piperidin-1 -yl)ethanon; 2-cyclopentyl-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)ethanon 9 l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(2-methylthiazol-5- yl)ethanon; N-cyclohexyl-N-hydroxy-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -c arboxamid; N-(4-(2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-oxoethyl)phe nyl)methansulfonamid; N-cyclopropyl-N-hydroxy-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-c arboxamid; 3,3-difluor-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)butan-1 -on l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(p-tolyl)ethanon; l-(l-(4-aminopyrimidin-2-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; l-(l-(2-aminopyrimidin-4-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-cyclopropyl-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxamid; 2-cyclopropyl-l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)ethano η; 2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyliden)acetonitril; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(4-(trifluormethyl)thiazol-2-yl)piper idin-1 -carboxamid; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benza mid; 1 -(4-( i -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(4-(methylsulfonyl) phenyl)ethanon; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4r)-4-methylcyclohexyl)piperidi n-1-carboxamid; l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-3,3-dimethylbutan-l- on; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benzen sulfonamid; N-(tert-butyl)-4-(2-(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-oxoethyl)benzensulfonamid; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benzoe syre; 1- (4-(difluormethylen)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(2,2,2-trifluorethyliden)cyclohexyl)ethanol; N-benzyl-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexancarboxami d; 4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)-N-phenylcyclohexancarboxami d; N-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)benzamid; 1 -(4-(2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexyl)-3-phenylurea; N-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)-2-phenylacetam id; eller et farmaceutisk acceptabelt salt deraf.
2. Sammensætning ifølge krav 1, hvor forbindelsen er 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id eller et farmaceutisk acceptabelt salt deraf.
3. Sammensætning ifølge krav 1, hvor forbindelsen er 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non eller et farmaceutisk acceptabelt salt deraf.
4. Sammensætning ifølge krav 1, hvor forbindelsen er 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenyletha non eller et farmaceutisk acceptabelt salt deraf.
5. Sammensætning ifølge krav 1, hvor forbindelsen er (S)-l-cyclohexyl-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol eller et farmaceutisk acceptabelt salt deraf.
6. Sammensætning ifølge krav 1, hvor forbindelsen er (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse med formlen
eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandlingen af sygdomme og forstyrrelser medieret af indoleamine-2,3-dioxygenase, hvor binding α er en enkelt- eller dobbeltbinding; n er 0, 1, 2, 3 eller 4; hvert R1 uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R eller -N(R)C(0)N(R)2; R2 er -Ci-4-alkyl-RA eller -C2-4-alkenyl-R3, når binding α er en enkeltbinding; og R2 er =C(H)Ra når binding α er en dobbeltbinding; hvor Ra er -CN, -C(0)R3, -C(0)0R3, -C(0)N(R3)(Rc), -C(ORB)(R3)(Rc), -C(NHRB)(R3)(Rc), eller -C(=N-ORc)R3, hvor Rb er hydrogen, Ci-6-alkyl, Ci-6-haloalkyl, -Ci-6-alkyl-RB1, -C(0)R3, -C(0)N(H)R3, eller -S(0)2R3, -C(0)(CH2)i-4C00R, -C(0)(CH2)i-4(NR)C00R, -C(0)CH(NH2)(Rd), -S(0)20R3, -S(0)2N(R3)2, -CH2-0P(0)2(0R)2 eller -P(0)(0R3)2, hvor RB1 er cyano, nitro, Ci-6-alkyl, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, eller -N(R)C(0)N(R)2; Rd er hydrogen, methyl, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)(CH2CH3), benzyl, 4-hydroxybenzyl, -CH2(3-indolyl), -CH2SH, -CH2CH2SCH3, -CH2OH, -CH(CH3)OH, -(CH2)4-NH2, -(CH2)3-N(H)C(=NH)NH2, -CH2(4-imidazolyl), -CH2COOH, -CH2CH2COOH, -CH2CONH2, -CH2CH2CONH2; hvert R3 uafhængigt er hydrogen, Ci-6-alkyl, Ci-6-haloalkyl, aryl, heteroaryl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-10-leddet heterocyclyl, arylCi-6-alkyl-, heteroarylCi-6-alkyl-, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, (3-10-leddet heterocyclyl)Ci-6-alkyl-, eller (heteroaryl)-(3-lO-leddet heterocyclyl)-, hvor alkyl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-10-leddet heterocyclyl, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, (3-10-leddet heterocyclyl)Ci-6-alkyl- og (heteroaryl)-(3-lO-leddet heterocyclyl)-, hver eventuelt er og uafhængigt substitueret med én =R32-gruppe og hver eventuelt substitueret og uafhængigt med én, to, tre eller fire R31-grupper; aryl, heteroaryl, arylCi-6-alkyl-, og heteroarylCi-6-alkylgrupper, hver eventuelt er substitueret med én, to, tre eller fire R31grupper; hvor hvert R31uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, -Ci-6-alkyl-R33, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)N(0H)R, -C(0)R, -C(NRu)R, -C(NRn)N(Ru)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, -N(R)C(0)N(R)2, hvor R33 er cyano, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, eller -N(R)C(0)N(R)2; R32 er =0, =S, =N(R), =N(OR), =C(R34)2, =(spiro-C3-8-cycloalkyl), eller =(spiro-(3-l O-leddet heterocyclyl)), hvor hvert R34 uafhængigt er hydrogen, halogen, cyano, Ci-6-alkyl, -Ci-6-alkyl-OR, Ci-6-haloalkyl, C3-8-cycloalkyl, eller 3-1 O-leddet heterocyclyl; eller begge R34 taget sammen med det atom, hvortil de begge er bundet, danner en monocyklisk C3-8-cycloalkyl eller monocyklisk 3-8-leddet heterocyclyl; Rc er hydrogen eller Ci-6-alkyl; og hvert R uafhængigt er hydrogen eller R10, hvor R10 er Ci-6-alkyl, Ci-6-haloalkyl, aryl, heteroaryl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-1 O-leddet heterocyclyl, arylCi-6-alkyl, heteroarylCi-6-alkyl-, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, eller (3-1 O-leddet heterocyclyl)Ci-6-alkyl-, hvert R10 eventuelt substitueret med én, to, tre eller fire grupper, der hver uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, Ci-e-haloalkyl, -OR11, -N(RU)2, -SR11, -C(0)0Rn, -C(0)N(Rn)2, -C(0)Rn, -S(0)Rn, -S(0)0Rn, -S(0)N(Rn)2, -S(0)2Rn, -S(0)20Rn, -S(0)2N(Rn)2, -0C(0)Rn, -0C(0)0Rn, -0C(0)N(Rn)2, -N(Rn)C(0)Rn, -N(Rn)C(0)0Rn, -N(Rn)C(0)N(Rn)2, -N(Rn)S(0)2Rn, eller -C(0)-(3-l O-leddet heterocyclyl), hvor hvert R1 Uafhængigt er hydrogen eller Ci-6-alkyl.
8. Forbindelse til anvendelse ifølge krav 7, der er 2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; ethyl 2-(5H-imidazo[5,1 -a]isoindol-5-yl)acetat; (E)-5-(2-bromstyryl)-5H-imidazo[5,1 -ajisoindol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanon; 2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl2-(((lR,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)a cetat; tert-butyl (4-(2-(5H-imidazo[5,l-a]isoindol-5-yl)acetyl)phenyl)carbamat; l-(4-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanon; tert-butyl (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)carbamat; l-(4-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(3-nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(3-nitrophenyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanol; tert-butyl (2-(2-(5H-imidazo[5,l-a]isoindol-5-yl)acetyl)phenyl)carbamat; tert-butyl (2-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)carbamat; 1 -(2-aminophenyl)-2-(5H-imidazo[5,l -a]isoindol-5-yl)ethanon; 1 -(2-aminophenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1- (2-chlorphenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanon; 1 -(5H-imidazo[5,1 -a]isoindol-5-yl)-2-methylpropan-2-ol; 1 -(2-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -(3 -chlorphenyl)-2 -(5 H-imidazo [5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -phenylethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -phenyl ethanol; 1-(2,4-dimethylfuran-3-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(3 -chlorphenyl)-2 -(5 H-imidazo [5,1 -a]isoindol-5-yl)ethanon; l-cyclohexyl-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanon; 1- cyclohexyl-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-4-yl)ethanol; 2-(7-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; (Z)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanonoxim; 1- cyclopentyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; tert-butyl 4-( 1 -hydroxy-2-(5 H-imidazo [5,1 -a] isoindol-5 -yl)ethyl)piperidin-1 -carboxylat; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanamin; tert-butyl (3-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)carbamat; 1 -(3-aminophenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 4- (2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 1 -cyclohexyl-2-(9-methoxy-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 5- (2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-9-ol; 2- (8-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 1 -(cyclohex-1 -en-1 -yl)-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethanol; 1- cyclohexyl-2-(8-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1,4-dioxaspiro[4.5]decan-8-yl)ethanol; 4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanon; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylencyclohexyl)ethanol; 1 -(cyclohex-3-en-l -yl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; l-(4-(hydroxymethyl)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)(thiophen-2-yl)methano η; 1 .(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)pip eridin-1 -yl)ethanon; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylencyclohexyl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-5-yl)ethanol; l-(4_(l_hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2,2-dimethylpropan- 1- on; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(furan-2-yl)ethanol; (1S)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (lR)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(iodomethylen)cyclohexyl)ethanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)propan-1 -ol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)acetonitril; 1 -cyclohexyl-3-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)propan-2-ol; 1 -cyclohexyl-3 -(5H-imidazo [5,1 -a]isoindol-5 -yl)propan-2-ol; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenylethanon; 1- (4,4-difluorcyclohcxyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)cthanol; 1 -(4,4-difluorcyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(l-methyl-lH-imidazol-5-yl)ethanol; 1- (4-(cyclopropylmethylen)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]Isoindol-5-yl)-l-(4-(propan-2-yliden)cyclohexyl)ethanol; (E)-5-(2-cyclohexylvinyl)-5H-imidazo[5,1 -a]isoindol; 2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; l-(cyclohex-3-en-l-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (S)-1 -cyclohexyl-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (R)-1 -cyclohexyl-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (R) -1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (S) -1 -cyclohexyl-2-((S)-5H-imidazo [5,1 -a]isoindol-5-yl)ethanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yliden)etanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethylacetat; l-(4-(2-(benzyloxy)ethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; l-(l-(benzylsulfonyl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; l-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(pyrimidin-5-yl)eth anon; 2-(3,4-difluorphenyl)-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl) ethanon; cyclohexyl(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)methanon; methyl 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylat; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylphenylcarbamat; 4-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethoxy)-4-oxosmørsyre; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylbenzoat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(2-(methylsulfonamido)ethyl)cycloh exancarboxamid; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl-2-amino-3-methylbutanoat; 1- cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyldihydrogenphosphat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylsyre; 1 .(4.( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(pyridin-4-yl)ethan on; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-(spiro[2.5]octan-6-yl)ethanol; 2-(4-fluorphenyl)-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)etha non; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl 2-aminopropanoat; l-(4-(2-hydroxyethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylpyrrolidin-2-carboxylat; (2S)-5-(l -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl) 1 -methyl-2-aminopentandioat; 1 _(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenylethanon; (3-fluor-2-hydroxyphenyl)(4-( 1-hydroxy-2-(5H-imidazo [5,1-a]isoindol-5-yl)ethyl)piperidin-1-yl)methanon; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboxamid; (4-fluorphenyl)(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)methano n; (2S)-2-amino-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l -yl)-3-phen ylpropan-1-on; (4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l -yl)((S)-pyrrolidin-2-yl) methanon; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexylbenzoat; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 1 -(3-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)azetidin-1 -yl)-2-phenylethanon; 3- (1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylazetidin-1 -carboxamid; tert-butyl 3 -(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)azetidin-1 -carboxylat; 1- (azetidin-3-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; tert-butyl 4- ((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxylat; 1 -((1 s,4s)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-3-yl)ethanol; (lr,4r)-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 4-((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxa mid; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboxam id; 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; (lR,4s)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4s)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lS,4r)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4r)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl )cyclohexanol; 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(tetrahydro-2H-pyran-4-yl)ethanon; 1- (4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-phenyletha non; N-((ls,4s)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; 1 -(4-((S)-1 -hydroxy-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; 2- (5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(1 -(phenylcarbamoyl)piperidin-4-yl)ethyl phenylcarbamat; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4R)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)p iperidin-1 -carboxamid; 4-((S)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4S)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; 1- ((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 .(4_((R)_ i -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(tetrahydro -2H-pyran-4-yl)ethanon; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-2-yl)ethanol; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)p iperidin-1 -carboxamid; N-cyclohexyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carbo xamid; N-((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; N-cyclopentyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carb oxamid; 2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-l -(4-(trifluormethyl)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(trifluormethyl)cyclohexyl)ethanol; 1 .(4_((R). i -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(4-(trifluor methyl)phenyl)ethanon; 4-((Æ)-l-hydroxy-2-((S)-5//-imidazo[5,l-a]isoindol-5-yl)ethyl)-./V-(4-(trifluormethyl)phenyl)pi peridin-1 -carboxamid; (4-((R)-1 -hydroxy-2-((S)-5//-imidazo[5,l -a]isoindol-5-yl)ethyl)piperidin-1 -yl)(lH-imidazol-1 -yl)methanon; 1 -(5H-imidazo[5,1 -a]isoindol-5-yl)-3-methylbutan-2-ol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-3-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(piperidin-3-yl)ethanol; l-cyclohexyl-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -cyclohexyl-3-(5H-imidazo [5,1 -a]isoindol-5-yl)propan-1 -ol; 1- cyclohexyl-2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)cthyl)phcnyl)-2-(tetrahydro-2H-pyran-4-y l)acetamid; 2- (5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(1 H-imidazol-2-yl)ethanol; 2-(5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -(1 H-imidazol-4-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(thiazol-2-yl)ethanol; (5S)-5-(2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-6-ol; 1- (2-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)acetamid; N-(2-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexyl)acetamid; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)-N-methylethanamin; 2- ((l-cyclohexyl-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)amino)ethansulfonamid; 2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -methylpiperidin-4-yl)ethanol; 1- (4-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)acetamid; 1 -(4-(aminomethyl)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexancarboxamid; 1 -(3-aminocyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyridin-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo [5,1 -a]isoindol-5 -yl)-1-((1 r,4r)-4-(pyridin-3 -ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyridin-4-ylmethoxy)cyclohexyl)ethanol; 1- ((lr,4r)-4-((2-aminopyridin-4-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyrazin-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-(pyrimidin-5-ylmethoxy)cyclohexyl)ethanol; 1 -((lr,4r)-4-((6-aminopyridin-2-yl)mcthoxy)cyclohcxyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ct hanol; 1 -((lr,4r)-4-((6-aminopyridin-3-yl)mcthoxy)cyclohexyl)-2-(5H-iniidazo[5,l-a]isoindol-5-yl)ct hanol; l-((lr,4r)-4-((3-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; 1 -((1 r,4r)-4-((2-aminopyrimidin-5-yl)methoxy)cyclohcxyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl) ethanol; 1-(( 1 r,4r)-4-((4-aminopyrimidin-5-yl)methoxy)cyclohcxyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl) ethanol; 1- ((lr,4r)-4-((5-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 2- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 3- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 4- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 2-((((lr,4r)-4-(l -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; methyl 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 3- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((1 r,4r)-4-methoxycyclohexyl)ethanol; 1- ((lr,4r)-4-ethoxycyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-isopropoxycyclohexyl)ethanol; l-((lr,4r)-4-(cyclopropylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- ((lr,4r)-4-(cyclopentylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(thiophen-2-ylmethoxy)cyclohexyl)ethanol; 1- ((lr,4r)-4-((lH-indol-3-yl)oxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -((1 r,4r)-4-(( 1 H-indol-5-yl)oxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-((tetrahydro-2H-pyran-4-yl)methoxy)cyclohexyl)etha nol; 4- (((4.(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)benzensulf onamid; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(oxazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(thiazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(l-(l-imino-2-phenylethyl)piperidin-4-yl)ethanol; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboximidamid; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(pyridin-4-yl)piperidin-l-carboximi damid; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)piperidin -1 -carboximidamid; N-(4-cyanophenyl)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxa mid; N-(tert-butyl)-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxamid; N-(tert-butyl)-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -sulfonamid; 1- (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(3-hydroxyphenyl) ethanon; 2- (1 -(azetidin-1 -carbonyl)piperidin-4-yl)-2-hydroxy-1 -(4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoi ndol-5 -yl)ethyl)piperidin-1 -yl)ethanon; 2-cyclopentyl-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)ethanon 5 1-(4-(1-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(2-methylthiazol-5-yl)ethanon; N-cyclohexyl-N-hydroxy-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -c arboxamid; N-(4-(2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-oxoethyl)phe nyl)methansulfonamid; N-cyclopropyl-N-hydroxy-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-c arboxamid; 3,3 -difluor-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)butan-1 -on 5 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(p-tolyl)ethanon; l-(l-(4-aminopyrimidin-2-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- (l-(2-ammopyrimidin-4-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-cyclopropyl-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxamid; 2- cyclopropyl-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)ethano n; 2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyliden)acetonitril; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(4-(trifluormethyl)thiazol-2-yl)piper idin-1 -carboxamid; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benza mid; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(4-(methylsulfonyl) phenyl)ethanon; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4r)-4-methylcyclohexyl)piperidi n-1-carboxamid; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidm-1 -yl)-3,3 -dimethylbutan-1 -on; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benzen sulfonamid; N-(tert-butyl)-4-(2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin- l-yl)-2-oxoethyl)benzensulfonamid; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benzoe syre; l_(4-(difluormethylen)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(2,2,2-trifluorethyliden)cyclohexyl)ethanol; N-benzyl-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexancarboxami d; 4_(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)-N-phenylcyclohexancarboxami d; N-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)benzamid; 1 -(4-(2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexyl)-3-phenylurea; N-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)-2-phenylacetam id; eller et farmaceutisk acceptabelt salt deraf.
9. Forbindelse til anvendelse ifølge krav 7, der er 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id, 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenyletha non, 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenyletha non, (S)-1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol, eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse med formlen,
eller et farmaceutisk acceptabelt salt deraf til anvendelse i behandling af indoleamin 2,3-dioxygenase- (IDO) medieret immunsuppression, hvor binding α er en enkelt- eller dobbeltbinding; n er 0, 1, 2, 3 eller 4; hvert R1 uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R eller -N(R)C(0)N(R)2; R2 er -Ci-4alkyl-RA eller -C2-4-alkenyl-R3, når binding α er en enkeltbinding; og R2 er =C(H)Ra når binding α er en dobbeltbinding; hvor Ra er -CN, -C(0)R3, -C(0)0R3, -C(0)N(R3)(Rc), -C(ORB)(R3)(Rc), -C(NHRB)(R3)(Rc) eller -C(=N-ORc)R3, hvor Rb er hydrogen, Ci-6-alkyl, Ci-6-haloalkyl, -Ci_6-alkyl-RB1, -C(0)R3, -C(0)N(H)R3, eller -S(0)2R3, -C(0)(CH2)i-4C00R, -C(0)(CH2)i-4(NR)C00R, -C(0)CH(NH2)(Rd), -S(0)20R3, -S(0)2N(R3)2, -CH2-0P(0)2(0R)2, eller -P(0)(0R3)2, hvor RB1 er cyano, nitro, Ci-6-alkyl, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, eller -N(R)C(0)N(R)2; Rd er hydrogen, methyl, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)(CH2CH3), benzyl, 4-hydroxybenzyl, -CH2(3-indolyl), -CH2SH, -CH2CH2SCH3, -CH2OH, -CH(CH3)OH, -(CH2)4-NH2, -(CH2)3-N(H)C(=NH)NH2, -CH2(4-imidazolyl), -CH2COOH, -CH2CH2COOH, -CH2CONH2, -CH2CH2CONH2; hvert R3 uafhængigt er hydrogen, Ci-6-alkyl, Ci-6-haloalkyl, aryl, heteroaryl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-10-leddet heterocyclyl, arylCi-6-alkyl-, heteroarylCi-6-alkyl-, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, (3-10-leddet heterocyclyl)Ci-6-alkyl-, eller (heteroaryl)-(3-l O-leddet heterocyclyl)-, hvor alkyl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-10-leddet heterocyclyl, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, (3-10-leddet heterocyclyl)Ci-6-alkyl- og (heteroaryl)-(3-lO-leddet heterocyclyl)-, hver eventuelt er og uafhængigt substitueret med én =R32-gruppe og hver eventuelt substitueret og uafhængigt med én, to, tre eller fire R31-grupper; aryl, heteroaryl, arylCi-6-alkyl- og heteroarylCi-6-alkyl-grupper, hver eventuelt er substitueret med én, to, tre eller fire R3øgrupper; hvor hvert R31 uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, -Ci-6-alkyl-R33, Ci-6-haloalkyl, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)N(0H)R, -C(0)R, -C(NRu)R, -C(NRn)N(Rn)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, -N(R)C(0)N(R)2, hvor R33 er cyano, -OR, -N(R)2, -SR, -C(0)0R, -C(0)N(R)2, -C(0)R, -S(0)R, -S(0)0R, -S(0)N(R)2, -S(0)2R, -S(0)20R, -S(0)2N(R)2, -0C(0)R, -0C(0)0R, -0C(0)N(R)2, -N(R)C(0)R, -N(R)C(0)0R, eller -N(R)C(0)N(R)2; R32 er =0, =S, =N(R), =N(OR), =C(R34)2, =(spiro-C3-8-cycloalkyl), eller =(spiro-(3-lO-leddet heterocyclyl)), hvor hvert R34 uafhængigt er hydrogen, halogen, cyano, Ci-6-alkyl, -Ci-6-alkyl-OR, Ci-6-haloalkyl, C3-8-cycloalkyl, eller 3-1 O-leddet heterocyclyl; eller begge R34 taget sammen med det atom, hvortil de begge er bundet, danner en monocyklisk C3-8-cycloalkyl eller monocyklisk 3-8-leddet heterocyclyl; Rc er hydrogen eller Ci-6-alkyl; og hvert R uafhængigt er hydrogen eller R10, hvor R10 er Ci-6-alkyl, Ci-6-haloalkyl, aryl, heteroaryl, C3-8-cycloalkyl, C3-8-cycloalkenyl, 3-1 O-leddet heterocyclyl, arylCi-6-alkyl, heteroarylCi-6-alkyl-, C3-8-cycloalkylCi-6-alkyl-, C3-8-cycloalkenylCi-6-alkyl-, eller (3-10-leddet heterocyclyl)Ci-6-alkyl-, hvert R10 eventuelt substitueret med én, to, tre eller fire grupper, der hver uafhængigt er halogen, cyano, nitro, Ci-6-alkyl, Ci-e-haloalkyl, -OR11, -N(RU)2, -SR11, -C(0)0Rn, -C(0)N(Rn)2, -C(0)Rn, -S(0)Rn, -S(0)0Rn, -S(0)N(Ru)2, -S(0)2Rn, -S(0)20Rn, -S(0)2N(RU)2, -0C(0)Rn, -0C(0)0Rn, -0C(0)N(Ru)2, -N(Rn)C(0)Rn, -N(Rn)C(0)0Rn, -N(R11)C(0)N(R11)2, -N(Rn)S(0)2Rn, eller -C(0)-(3-lO-leddet heterocyclyl), hvor hvert R11 uafhængigt er hydrogen eller Ci-6-alkyl.
11. Forbindelse til anvendelse ifølge krav 10, der er 2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; ethyl 2-(5H-imidazo[5,l-a]isoindol-5-yl)acetat; (E)-5-(2-bromstyryl)-5H-imidazo[5,l-a]isoindol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 2-(6-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanon; 2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl2-(((lR,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)a cetat; tert-butyl (4-(2-(5H-imidazo[5,l-a]isoindol-5-yl)acetyl)phenyl)carbamat; l-(4-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanon; tert-butyl (4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)phenyl)carbamat; l-(4-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(3-nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(3-nitrophenyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(2-nitrophenyl)ethanol; tert-butyl (2-(2-(5H-imidazo[5,l-a]isoindol-5-yl)acetyl)phenyl)carbamat; tert-butyl (2-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)phenyl)carbamat; l-(2-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanon; 1- (2-aminophenyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(2-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanon; 1 -(5H-imidazo[5,1 -a]isoindol-5-yl)-2-methylpropan-2-ol; 1 -(2-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -(3-chlorphenyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5 -yl)-1 -phenylethanon; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -phenylethanol; l-(2,4-dimethylfuran-3-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(3 -chlorphenyl)-2 -(5 H-imidazo [5,1 -a]isoindol-5-yl)ethanon; l-cyclohexyl-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanon; 1- cyclohexyl-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo [5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-4-yl)ethanol; 2-(7-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; (Z)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanonoxim; 1 -cyclopentyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; tert-butyl 4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -carboxylat; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanamin; tert-butyl (3-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)phenyl)carbamat; 1 -(3 -aminophenyl)-2-(5 H-imidazo [5,1 -a]isoindol-5-yl)ethanol; 4- (2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 1 -cyclohexyl-2-(9-methoxy-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 5- (2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-9-ol; 2-(8-chlor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -cyclohexylethanol; 1 -(cyclohex-1 -en-1 -yl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1- cyclohexyl-2-(8-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(l,4-dioxaspiro[4.5]decan-8-yl)ethanol; 4-(2-(6-fluor-5 H-imidazo [5,1 -a] isoindol-5 -yl)-l -hydroxyethyl)cyclohexanon; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylencyclohexyl)ethanol; 1 -(cyclohex-3-en-1 -yl)-2-(5 H-imidazo [5,1 -a] isoindol-5-yl)ethanol; 1- (4_(hydroxymethyl)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)(thiophen-2-yl)methano n; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)ethanon; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-methylencyclohexyl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(thiazol-5-yl)ethanol; 1 -(4-( i -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l-yl)-2,2-dimethylpropan- 1- on; 2- (6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(furan-2-yl)ethanol; (1S)-1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (lR)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(iodomethylen)cyclohexyl)ethanol; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a] isoindol-5-yl)propan-1 -ol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)acetonitril; 1 -cyclohexyl-3-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)propan-2-ol; 1 -cyclohexyl-3 -(5H-imidazo [5,1 -a]isoindol-5 -yl)propan-2-ol; 1 -(4-( i -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenylethanon; l-(4,4-difluorcyclohcxyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)cthanol; 1- (4,4-difluorcyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(l-methyl-lH-imidazol-5-yl)ethanol; 1- (4-(cyclopropylmethylen)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(propan-2-yliden)cyclohexyl)ethanol; (E)-5-(2-cyclohexylvinyl)-5H-imidazo[5,1 -a]isoindol; 2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-methylcyclohexyl)ethanol; l-(cyclohex-3-en-l-yl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (S)-1 -cyclohexyl-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; (R)-l-cyclohexyl-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (R) -1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a] isoindol-5-yl)ethanol; (S) -1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yliden)etanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylacetat; l-(4-(2-(benzyloxy)ethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; l-(l-(benzylsulfonyl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- (4-(1-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(pyrimidin-5-yl)eth anon; 2- (3,4-difluorphenyl)-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl) ethanon; cyclohexyl(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)methanon; methyl 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylat; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylphenylcarbamat; 4-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethoxy)-4-oxosmørsyre; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexanol; l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylbenzoat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(2-(methylsulfonamido)ethyl)cycloh exancarboxamid; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl-2-amino-3-methylbutanoat; 1- cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyldihydrogenphosphat; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxylsyre; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(pyridin-4-yl)ethan on; 2- (5H-imidazo[5,l-a]isoindol-5-yl)-l-(spiro[2.5]octan-6-yl)ethanol; 2-(4-fluorphenyl)-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)etha non; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl-2-aminopropanoat; 1-(4-(2-hydroxyethyliden)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; (2S)-l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethylpyrrolidin-2-carboxylat; (2S)-5-(l -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl) 1 -methyl-2-aminopentandioat; 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenyletha non; (3-fluor-2-hydroxyphenyl)(4-( 1-hydroxy-2-(5H-imidazo [5,1-a]isoindol-5-yl)ethyl)piperidin-1-yl)methanon; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboxamid; (4-fluorphenyl)(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)methano η; (2S)-2-amino-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-3-phen ylpropan-1-on; (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)((S)-pyrrolidin-2-yl)met hanon; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl benzoat; (lR,4s)-4-(2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl) cyclohexanol; 1 -(3-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)azetidin-1 -yl)-2-phenylethanon; 3- (1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylazetidin-1 -carboxamid; tert-butyl 3-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)azetidin-1 -carboxylat; 1- (azetidin-3-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; tert-butyl 4- ((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxylat; tert-butyl 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxylat; 1 -((1 s,4s)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-3-yl)ethanol; (lr,4r)-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 4-((S)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((R)-l-hydroxy-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxa mid; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboxam id; 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; (lR,4s)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (1 S,4s)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4s)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lS,4r)-4-((S)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (1 S,4r)-4-((S)-2-((R)-6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; (lR,4r)-4-((R)-2-((R)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol; 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(tetrahydro-2H-pyran-4-yl)ethanon; 1 -(4-((R)-1 -hydroxy-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-l -yl)-2-phenyletha non; N-((ls,4s)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; 1 -(4-((S)-l -hydroxy-2-((R)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenyletha non; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -(phenylcarbamoyl)piperidin-4-yl)ethylphenylcarbama t; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4R)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; 4-((S)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)p iperidin-1 -carboxamid; 4-((S)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4S)-4-hydroxycyclohex yl)piperidin-1 -carboxamid; l-((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- ((lr,4r)-4-(benzyloxy)cyclohexyl)-2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(tetrahydro -2H-pyran-4-yl)ethanon; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-4-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(pyridin-2-yl)ethanol; 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)p iperidin-1 -carboxamid; N-cyclohexyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carbo xamid; N-((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)benzamid; N-cyclopentyl-4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carb oxamid; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(trifluormethyl)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(trifluormethyl)cyclohexyl)ethanol; 1 _(4_((R)_ i -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-(4-(trifluor methyl)phenyl)ethanon; 4-((R)-1 -hydroxy-2-((S)-5//-imidazo[5,l -a]isoindol-5-yl)ethyl)-A^-(4-(trifluormethyl)phenyl)pi peridin-1 -carboxamid; (4-((R)-1 -hydroxy-2-((£')-5//-imidazo[5,l -a]isoindol-5-yl)ethyl)piperidin-1 -yl)(lH-imidazol-1 -yl)methanon; 1 -(5H-imidazo[5,1 -a]isoindol-5-yl)-3-methylbutan-2-ol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(tetrahydro-2H-pyran-3-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(piperidin-3-yl)ethanol; l-cyclohexyl-2-((R)-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -cyclohexyl-3-(5H-imidazo[5,1 -a]isoindol-5-yl)propan-1 -ol; 1- cyclohexyl-2-(9-fluor-5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)phenyl)-2-(tetrahydro-2H-pyran-4-y l)acetamid; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 H-imidazol-2-yl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 H-imidazol-4-yl)ethanol; 2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-(thiazol-2-yl)ethanol; (5S)-5-(2-cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,l-a]isoindol-6-ol; 1 -(2-aminocyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; N-(l-cyclohexyl-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)acetamid; N-(2-( 1 -hydroxy-2-(5 H-imidazo [5,1 -a]isoindol-5 -y l)ethyl)cyclohexyl)acetamid; 1 -cyclohexyl-2-(5H-imidazo[5,1 -a]isoindol-5-yl)-N-methylethanamin; 2-((l-cyclohexyl-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)amino)ethansulfonamid; 2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -methylpiperidin-4-yl)ethanol; l-(4-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)acetamid; l-(4-(aminomethyl)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexancarboxamid; l-(3-aminocyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-((lr,4r)-4-(pyridin-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((1 r,4r)-4-(pyridin-3-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((1 r,4r)-4-(pyridin-4-ylmethoxy)cyclohexyl)ethanol; 1- ((lr,4r)-4-((2-aminopyridin-4-yl)mcthoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ct hanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((1 r,4r)-4-(pyrazin-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((1 r,4r)-4-(pyrimidin-5-ylmethoxy)cyclohexyl)ethanol; 1 -((1 r,4r)-4-((6-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((6-aminopyridin-3-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((3-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)et hanol; l-((lr,4r)-4-((2-aminopyrimidin-5-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl) ethanol; 1- ((lr,4r)-4-((4-aminopyrimidin-5-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl) ethanol; 1 -((lr,4r)-4-((5-aminopyridin-2-yl)methoxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)et hanol; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 2- (((( 1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)-N, N-dimethylbenzamid; 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 3 -((((1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 2- (((( 1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zensulfonamid; 4-(((( lr,4r)-4-(l -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 3- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; 2- (((( 1 r,4r)-4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)cyclohexyl)oxy)methyl)ben zamid; methyl 4-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 3- ((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; methyl 2-((((lr,4r)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)ben zoat; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-methoxycyclohexyl)ethanol; 1 -((lr,4r)-4-ethoxycyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2-(5H-imidazo [5,1 -a]isoindol-5 -yl)-1 -((1 r,4r)-4-isopropoxycyclohexyl)ethanol; l-((lr,4r)-4-(cyclopropylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- ((lr,4r)-4-(cyclopentylmethoxy)cyclohexyl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 2- (5H-imidazo[5,1 -a]isoindol-5-yl)-1 -((lr,4r)-4-(thiophen-2-ylmethoxy)cyclohexyl)ethanol; 1 -((1 r,4r)-4-(( 1 H-indol-3-yl)oxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 1 -((1 r,4r)-4-(( 1 H-indol-5-yl)oxy)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-((tetrahydro-2H-pyran-4-yl)methoxy)cyclohexyl)etha nol; 4- (((4-(1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)cyclohexyl)oxy)methyl)benzensulf onamid; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(oxazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(4-(thiazol-2-ylmethoxy)cyclohexyl)ethanol; 2-(5H-imidazo[5,1 -a]isoindol-5-yl)-1 -(1 -(1 -imino-2-phenylethyl)piperidin-4-yl)ethanol; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-phenylpiperidin-1 -carboximidamid; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(pyridin-4-yl)piperidin-1 -carboximi damid; 4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)-N-(tetrahydro-2H-pyran-4-yl)piperidin -1 -carboximidamid; N-(4-cyanophenyl)-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxa mid; N-(tert-butyl)-4-(l -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -carboxamid; N-(tert-butyl)-4-(l -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -sulfonamid; 1- (4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(3-hydroxyphenyl) ethanon; 2- (1 -(azetidin-1 -carbonyl)piperidin-4-yl)-2-hydroxy-1 -(4-(1 -hydroxy-2-(5H-imidazo[5,1 -a] isoi ndol-5 -yl)ethyl)piperidin-1 -yl)ethanon; 2-cyclopentyl-1 -(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)ethanon 5 1-(4-(1-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-(2-methylthiazol-5-yl)ethanon; N-cyclohexyl-N-hydroxy-4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -c arboxamid; N-(4-(2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-oxoethyl)phe nyl)methansulfonamid; N-cyclopropyl-N-hydroxy-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-c arboxamid; 3,3 -difluor-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)butan-1 -on 5 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(p-tolyl)ethanon; l-(l-(4-aminopyrimidin-2-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; 1- (l-(2-aminopyrimidin-4-yl)piperidin-4-yl)-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethanol; N-cyclopropyl-4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-carboxamid; 2- cyclopropyl-1-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)ethano n; 2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)cyclohexyliden)acetonitril; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-(4-(trifluormethyl)thiazol-2-yl)piper idin-1 -carboxamid; 4-(2-(4-(1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benza mid; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-(4-(methylsulfonyl) phenyl)ethanon; 4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-((lr,4r)-4-methylcyclohexyl)piperidi n-1-carboxamid; 1 -(4-( 1 -hydroxy-2-(5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-3,3 -dimethylbutan-1 - on; 4-(2-(4-(l-hydroxy-2-(5H-imidazo[5,l-a]isoindol-5-yl)ethyl)piperidin-l-yl)-2-oxoethyl)benzen sulfonamid; N-(tert-butyl)-4-(2 -(4-( 1 -hydroxy-2-(5 H-imidazo [5,1 -a] isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-o xoethyl)benzensulfonamid; 4-(2-(4-( 1 -hydroxy-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-oxoethyl)benzoe syre; 1 -(4-(difluormethylen)cyclohexyl)-2-(5H-imidazo[5,1 -a]isoindol-5-yl)ethanol; 2-(5H-imidazo[5,l-a]isoindol-5-yl)-l-(4-(2,2,2-trifluorethyliden)cyclohexyl)ethanol; N-benzyl-4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexancarboxami d; 4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)-N-phenylcyclohexancarboxami d; N-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)benzamid; l-(4-(2-(6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexyl)-3-phenylurea; N-(4-(2-(6-fluor-5H-imidazo[5,1 -a]isoindol-5-yl)-1 -hydroxyethyl)cyclohexyl)-2-phenylacetam id eller et farmaceutisk acceptabelt salt deraf.
12. Forbindelse til anvendelse ifølge krav 10, der er 4-((R)-l-hydroxy-2-((S)-5H-imidazo[5,l-a]isoindol-5-yl)ethyl)-N-phenylpiperidin-l-carboxam id, 1 -(4-((R)-1 -hydroxy-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethyl)piperidin-1 -yl)-2-phenylethanon, 1 -(4-((S)-1 -hydroxy-2-((S)-5H-imidazo [5,1 -a]isoindol-5 -yl)ethyl)piperidin-1 -yl)-2-phenyletha non, (S)-1 -cyclohexyl-2-((S)-5H-imidazo[5,1 -a]isoindol-5-yl)ethanol (lR,4r)-4-((R)-2-((S)-6-fluor-5H-imidazo[5,l-a]isoindol-5-yl)-l-hydroxyethyl)cyclohexanol, eller et farmaceutisk acceptabelt salt deraf.
13. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 10-12, hvor immunsuppressionen er associeret med cancer.
14. Forbindelse til anvendelse ifølge krav 13, hvor canceren er colon-, pancreas-, bryst-, prostata-, lunge-, hjerne-, ovarie-, cervix-, testikel-, nyre-, hoved- eller halscancer eller lymfom, leukæmi eller melanom.
DK15197593.5T 2011-04-15 2012-04-12 Kondenserede imidazolderivater anvendt som ido-inhibitorer DK3018132T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
EP12715295.7A EP2697227B1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
DK3018132T3 true DK3018132T3 (da) 2018-03-12

Family

ID=45976556

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15197593.5T DK3018132T3 (da) 2011-04-15 2012-04-12 Kondenserede imidazolderivater anvendt som ido-inhibitorer
DK12715295.7T DK2697227T3 (da) 2011-04-15 2012-04-12 Kondenserede imidazolderivater anvendt som ido-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12715295.7T DK2697227T3 (da) 2011-04-15 2012-04-12 Kondenserede imidazolderivater anvendt som ido-inhibitorer

Country Status (30)

Country Link
US (5) US9260434B2 (da)
EP (3) EP3018132B1 (da)
JP (4) JP2014511876A (da)
KR (1) KR102164443B1 (da)
CN (2) CN105111210B (da)
AU (4) AU2012242871C1 (da)
BR (1) BR112013026494A2 (da)
CA (1) CA2833296C (da)
CL (1) CL2013002990A1 (da)
CO (1) CO6862146A2 (da)
CY (1) CY1117440T1 (da)
DK (2) DK3018132T3 (da)
ES (2) ES2569665T3 (da)
HK (1) HK1256355A1 (da)
HR (2) HRP20160369T1 (da)
HU (2) HUE038586T2 (da)
IL (3) IL228862A (da)
LT (1) LT3018132T (da)
ME (1) ME02417B (da)
MX (1) MX340442B (da)
NO (1) NO2694640T3 (da)
NZ (2) NZ708090A (da)
PE (2) PE20181023A1 (da)
PL (2) PL3018132T3 (da)
PT (1) PT3018132T (da)
RS (2) RS56992B1 (da)
RU (2) RU2017107026A (da)
SI (2) SI2697227T1 (da)
SM (1) SMT201600130B (da)
WO (1) WO2012142237A1 (da)

Families Citing this family (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (da) 2011-04-15 2018-03-17
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
BR112015022575B1 (pt) * 2013-03-14 2022-03-22 Curadev Pharma Private Ltd Composto, pró-drogas de um composto, composição e método para preparar um composto
KR20150126623A (ko) * 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (zh) * 2013-08-06 2015-06-03 信实生物医药（上海）有限公司 一种3-氯-7(5)-溴苯并异恶唑的合成方法
DK3087071T3 (da) 2013-12-24 2019-01-02 Bristol Myers Squibb Co Tricykliske forbindelser som anticancermidler
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
HRP20192098T1 (hr) 2014-06-06 2020-02-21 Bristol-Myers Squibb Company Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
EP3189054B1 (en) 2014-09-05 2019-07-24 Merck Patent GmbH (1-fluoro-cyclohex-1-yl)-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
WO2016067035A1 (en) 2014-10-29 2016-05-06 Bicycle Therapeutics Limited Bicyclic peptide ligands specific for mt1-mmp
SMT202000413T1 (it) 2014-11-21 2020-09-10 Bristol Myers Squibb Co Anticorpi nei confronti di cd73 e loro usi
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
CN110256558B (zh) 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN105884828A (zh) 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
ES2789331T3 (es) 2015-03-02 2020-10-26 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
CN107743481A (zh) 2015-04-03 2018-02-27 百时美施贵宝公司 用于治疗癌症的吲哚胺2,3‑双加氧酶抑制剂
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
JP6806342B2 (ja) * 2015-04-10 2021-01-06 ベイジーン リミテッド インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
US10358451B2 (en) 2015-04-12 2019-07-23 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as IDO and TDO inhibitors
ES2857076T3 (es) 2015-04-13 2021-09-28 Five Prime Therapeutics Inc Terapia de combinación para cáncer
MX372919B (es) * 2015-04-21 2020-04-27 Jiangsu Hengrui Medicine Co Derivado de imidazol-isoindol, su metodo de preparacion y su uso medico.
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
CN108137687B (zh) 2015-05-29 2021-10-29 百时美施贵宝公司 抗ox40抗体及其用途
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 成都海创药业有限公司 一种氘代的ido抑制剂及其制备方法和用途
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
CN108137597A (zh) 2015-07-28 2018-06-08 百时美施贵宝公司 TGFβ受体拮抗剂
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20180250303A1 (en) 2015-08-25 2018-09-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106478634B (zh) * 2015-09-01 2020-05-22 尚华医药科技(江西)有限公司 稠合咪唑化合物、其制备方法、药物组合物和用途
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
CN108884139A (zh) 2015-11-02 2018-11-23 戊瑞治疗有限公司 Cd80胞外域多肽及其在癌症治疗中的用途
JP2018532406A (ja) * 2015-11-09 2018-11-08 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｄｏ１および／またはｔｄｏ修飾因子を同定するためのスクリーニングアッセイ
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
KR102777244B1 (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
WO2017107979A1 (en) 2015-12-24 2017-06-29 Genentech, Inc. Tdo2 inhibitors
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
WO2017134555A1 (en) 2016-02-02 2017-08-10 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CA3015012A1 (en) 2016-02-19 2017-08-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound serving as immunomodulator
WO2017140835A1 (en) 2016-02-19 2017-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
TW201736373A (zh) * 2016-02-19 2017-10-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 作為免疫調節劑的三並環化合物
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
KR102414558B1 (ko) 2016-04-18 2022-06-29 셀덱스 쎄라퓨틱스, 인크. 인간 cd40에 결합하는 효능성 항체 및 이의 용도
CN105732643A (zh) * 2016-04-18 2016-07-06 苏州大学 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
CN107312005B (zh) * 2016-04-27 2021-12-17 上海翰森生物医药科技有限公司 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
US10544099B2 (en) 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2017192811A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190004742A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
KR20190004743A (ko) 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107556316B (zh) * 2016-06-30 2021-11-12 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN105902542A (zh) * 2016-05-16 2016-08-31 张阳 一种偶联物在制备治疗心血管疾病药物中的应用
CN106957318B (zh) * 2016-05-19 2019-12-10 中国科学院上海有机化学研究所 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
WO2017201528A1 (en) 2016-05-20 2017-11-23 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
JOP20170131B1 (ar) 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
CN107488179B (zh) * 2016-06-11 2024-06-07 鲁南制药集团股份有限公司 含桥环的咪唑醇衍生物
CN107556315B (zh) * 2016-06-30 2021-08-31 鲁南制药集团股份有限公司 含四元环的咪唑衍生物
CN117683135A (zh) 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN107698594A (zh) * 2016-08-09 2018-02-16 苏州国匡医药科技有限公司 吲哚胺2，3‑双加氧酶抑制剂及其在药学中的用途
KR20190040990A (ko) 2016-08-26 2019-04-19 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 含咪唑稠合三环类化合物及其应用
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
US10882856B2 (en) 2016-09-24 2021-01-05 Beigene, Ltd. 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN108778332B (zh) * 2016-10-21 2019-10-18 苏州盛迪亚生物医药有限公司 Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
CN108884099B (zh) * 2016-10-21 2021-10-08 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
WO2018083635A2 (en) 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
CN106474468B (zh) * 2016-11-23 2020-03-27 中国医学科学院医学生物学研究所 一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
EP3560928B1 (en) * 2016-12-20 2021-10-20 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
TWI818902B (zh) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
CN108239091B (zh) * 2016-12-26 2021-08-13 中国医学科学院药物研究所 1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
US11173145B2 (en) 2017-01-17 2021-11-16 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
EP3601353A1 (en) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 成都海博锐药业有限公司 一种ido抑制剂化合物、药用组合物、用途
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
EP3645537A1 (en) 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
US11603373B2 (en) 2017-06-28 2023-03-14 Genentech, Inc. TDO2 and IDO1 inhibitors
AU2018294314B2 (en) 2017-06-30 2024-09-19 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
EP3658565B1 (en) 2017-07-28 2022-11-09 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
CN109983019B (zh) * 2017-08-08 2021-12-21 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物的制备方法
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
WO2019034725A1 (en) 2017-08-17 2019-02-21 Idorsia Pharmaceuticals Ltd INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHAN DIOXYGENASE
CN111163766A (zh) 2017-08-17 2020-05-15 医肯纳肿瘤学公司 Ahr抑制剂和其用途
EP3670518A4 (en) * 2017-08-18 2021-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC COMPOUND CRYSTALS
KR20250021628A (ko) 2017-08-31 2025-02-13 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
EP4176876A1 (en) 2017-09-14 2023-05-10 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
EP3684365A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND USES OF SUCH
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
JP7254821B2 (ja) 2017-10-16 2023-04-10 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
US12209079B2 (en) 2017-10-19 2025-01-28 General Incorporated Association Pharma Valley Project Supporting Organization IDO/TDO inhibitor
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
JP7167146B2 (ja) 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
US11472788B2 (en) 2017-11-25 2022-10-18 Beigene, Ltd. Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019138107A1 (en) 2018-01-15 2019-07-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 脒类和胍类衍生物、其制备方法及其在医药上的应用
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
CN111801341B (zh) 2018-03-08 2023-10-24 百时美施贵宝公司 作为抗癌剂的环二核苷酸
CA3094336A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
KR102874694B1 (ko) 2018-03-21 2025-10-23 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
US20210147570A1 (en) 2018-04-12 2021-05-20 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
HRP20231253T1 (hr) 2018-06-27 2024-02-02 Bristol-Myers Squibb Company Supstituirani spojevi naftiridina korisni kao aktivatori t stanica
PL3814347T3 (pl) 2018-06-27 2023-07-24 Bristol-Myers Squibb Company Związki naftyrydynonu użyteczne jako aktywatory komórek t
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
MX2021000009A (es) 2018-07-09 2021-03-09 Five Prime Therapeutics Inc Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116574105B (zh) * 2018-09-27 2025-10-10 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
MX2021005708A (es) 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
PH12021500026A1 (en) 2018-11-30 2022-05-11 Kymera Therapeutics Inc Irak degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
BR112021018506A2 (pt) 2019-03-19 2021-11-30 Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron Terapia de combinação para tratamento do câncer
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US20220259212A1 (en) 2019-07-11 2022-08-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
BR112022004831A2 (pt) 2019-09-19 2022-06-07 Bristol Myers Squibb Co Anticorpos que se ligam a vista em ph ácido
CN114728950B (zh) 2019-11-19 2024-10-18 百时美施贵宝公司 可作为helios蛋白质抑制剂的化合物
MX2022006308A (es) 2019-11-26 2022-06-22 Ikena Oncology Inc Derivados de carbazol polimorfos y usos de los mismos.
BR112022009944A2 (pt) 2019-11-26 2022-08-09 Bristol Myers Squibb Co Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
CN111333653A (zh) * 2019-12-16 2020-06-26 山东大学 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4081524B1 (en) 2019-12-23 2025-01-29 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as t cell activators
AU2020412698A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted piperazine derivatives useful as T cell activators
KR20220119456A (ko) 2019-12-23 2022-08-29 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
WO2021133751A1 (en) 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
BR112022013424A2 (pt) 2020-01-06 2022-12-13 Hifibio Hk Ltd Anticorpo anti-tnfr2 e seus usos
IL294466A (en) 2020-01-07 2022-09-01 Hifibio Hk Ltd Anti-galectin-9 antibody and uses thereof
AR121047A1 (es) 2020-01-15 2022-04-13 Blueprint Medicines Corp Inhibidores de map4k1
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
AU2021316053A1 (en) 2020-07-30 2023-03-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
IL300537A (en) 2020-08-10 2023-04-01 Gv20 Therapeutics Llc Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
IL300450A (en) 2020-08-17 2023-04-01 Bicycletx Ltd Bicyclic conjugates specific to nectin-4 and uses thereof
AU2021360782A1 (en) 2020-10-14 2023-06-08 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN117015531A (zh) 2020-12-02 2023-11-07 医肯纳肿瘤学公司 Tead抑制剂及其用途
JP2024501207A (ja) 2020-12-16 2024-01-11 ゴッサマー バイオ サービシズ、インコーポレイテッド Ｔ細胞活性化剤として有用な化合物
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20230113202A1 (en) 2021-02-02 2023-04-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
MX2023009379A (es) 2021-02-12 2023-10-10 Hoffmann La Roche Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
TW202245789A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4301358A2 (en) 2021-03-05 2024-01-10 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
CN117295737A (zh) 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
EP4305041A1 (en) 2021-03-08 2024-01-17 Blueprint Medicines Corporation Map4k1 inhibitors
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
IL307338A (en) 2021-04-05 2023-11-01 Bristol Myers Squibb Co Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
EP4320112B1 (en) 2021-04-06 2025-05-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
MX2023011933A (es) 2021-04-09 2024-01-05 Nimbus Clio Inc Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
CA3215081A1 (en) 2021-04-16 2022-10-20 Alfredo C. Castro Mek inhibitors and uses thereof
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
AU2022312496A1 (en) 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
CN117940406A (zh) 2021-07-15 2024-04-26 缆图药品公司 Map4k1抑制剂
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AR127505A1 (es) 2021-10-29 2024-01-31 Kymera Therapeutics Inc Degradadores irak-4 y síntesis de los mismos
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
EP4532470A1 (en) 2022-05-25 2025-04-09 Ikena Oncology, Inc. Mek inhibitors and uses thereof
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
KR20250057801A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 아릴-트라이아졸릴 및 관련 gpr84 길항제 및 이의 용도
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
KR20250046309A (ko) 2022-08-08 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
JP2025526683A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
PE20251399A1 (es) 2022-08-11 2025-05-22 Hoffmann La Roche Derivados de tetrahidrotiazepina biciclicos
AR130167A1 (es) 2022-08-11 2024-11-13 Hoffmann La Roche Derivados bicíclicos de tetrahidroazepina
EP4568959A1 (en) 2022-08-11 2025-06-18 F. Hoffmann-La Roche AG Bicyclic tetrahydrothiazepine derivatives
TW202430148A (zh) 2022-11-22 2024-08-01 美商皮克醫療公司 ｅＩＦ４Ｅ抑制劑及其用途
CN116143726B (zh) * 2022-12-02 2024-09-06 广州市联瑞制药有限公司 一种环磷腺苷杂质的制备方法
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2024233514A1 (en) 2023-05-08 2024-11-14 Bristol-Myers Squibb Company Substituted phenyl oxazolone compounds
AU2024269298A1 (en) 2023-05-10 2025-11-27 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
EP4615455A2 (en) 2023-06-23 2025-09-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
TW202525802A (zh) 2023-09-02 2025-07-01 美商必治妥美雅史谷比公司 經取代之苯基氧代㗁唑基哌啶二酮化合物
WO2025059245A1 (en) 2023-09-13 2025-03-20 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE40106T1 (de) 1983-05-18 1989-02-15 Ciba Geigy Ag Cyclohexandion-carbonsaeurederivate mit herbizider und das pflanzenwachstum regulierender wirkung.
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
CA2483451C (en) 2002-04-12 2014-07-29 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
JP4921965B2 (ja) 2003-03-27 2012-04-25 ランケナー インスティテュート フォー メディカル リサーチ 癌治療新規方式
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
ES2401482T3 (es) * 2005-05-10 2013-04-22 Incyte Corporation Moduladores de la indolamina 2,3-dioxigenasa y métodos de uso de los mismos
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
TWI382974B (zh) 2005-12-20 2013-01-21 英塞特公司 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
WO2008115804A1 (en) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
CA2932121A1 (en) * 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
NZ586069A (en) 2007-12-19 2012-05-25 Amgen Inc Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
WO2009132238A2 (en) * 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
HRP20141094T1 (hr) 2008-07-08 2015-01-16 Incyte Corporation 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
NO2694640T3 (da) 2011-04-15 2018-03-17
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
BR112015022575B1 (pt) 2013-03-14 2022-03-22 Curadev Pharma Private Ltd Composto, pró-drogas de um composto, composição e método para preparar um composto
KR20150126623A (ko) 2013-03-14 2015-11-12 뉴링크 제네틱스 코퍼레이션 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
JP6313415B2 (ja) 2013-03-15 2018-04-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
HRP20180971T1 (hr) 2013-03-15 2018-08-10 Bristol-Myers Squibb Company Inhibitori indolamin 2,3-dioksigenaze (ido)
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
MX366875B (es) 2013-07-11 2019-07-29 Bristol Myers Squibb Co Inhibidores de indoleamina 2,3-dioxigenasa (ido).

Also Published As

Publication number Publication date
HRP20160369T1 (hr) 2016-06-03
AU2012242871A1 (en) 2013-10-31
IL228862A0 (en) 2013-12-31
PL3018132T3 (pl) 2018-05-30
BR112013026494A2 (pt) 2016-12-27
US9388191B2 (en) 2016-07-12
AU2012242871B2 (en) 2014-09-11
AU2014274564B2 (en) 2016-10-06
EP3348558A1 (en) 2018-07-18
PE20181023A1 (es) 2018-06-27
DK2697227T3 (da) 2016-04-25
AU2018202706A1 (en) 2018-05-10
US20190225618A1 (en) 2019-07-25
IL241846A (en) 2016-06-30
US9260434B2 (en) 2016-02-16
ES2660831T3 (es) 2018-03-26
ME02417B (me) 2016-09-20
HK1193822A1 (zh) 2014-10-03
CL2013002990A1 (es) 2014-07-04
RS56992B1 (sr) 2018-05-31
EP2697227A1 (en) 2014-02-19
HRP20180335T1 (hr) 2018-04-20
HK1256355A1 (en) 2019-09-20
NZ708090A (en) 2016-12-23
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
WO2012142237A8 (en) 2012-11-22
US20140066625A1 (en) 2014-03-06
ES2569665T3 (es) 2016-05-12
US9850248B2 (en) 2017-12-26
NZ723271A (en) 2018-03-23
HUE027316T2 (en) 2016-10-28
JP2015061877A (ja) 2015-04-02
AU2012242871C1 (en) 2017-02-02
US20180118753A1 (en) 2018-05-03
EP3018132A1 (en) 2016-05-11
RU2017107026A3 (da) 2019-01-23
KR102164443B1 (ko) 2020-10-12
KR20140059167A (ko) 2014-05-15
CY1117440T1 (el) 2017-04-26
RU2613579C2 (ru) 2017-03-17
EP2697227B1 (en) 2016-02-03
SI3018132T1 (en) 2018-04-30
IL228862A (en) 2015-10-29
CN103547579B (zh) 2017-02-15
RU2017107026A (ru) 2019-01-23
SI2697227T1 (sl) 2016-06-30
WO2012142237A1 (en) 2012-10-18
AU2016277574A1 (en) 2017-01-12
CA2833296C (en) 2020-12-08
RS54723B1 (sr) 2016-08-31
MX2013012021A (es) 2014-07-10
PT3018132T (pt) 2018-03-09
CN103547579A (zh) 2014-01-29
HUE038586T2 (hu) 2018-10-29
IL246515B (en) 2018-08-30
AU2014274564A1 (en) 2015-01-22
JP5837673B2 (ja) 2015-12-24
NZ616457A (en) 2015-05-29
JP2017149769A (ja) 2017-08-31
US10233190B2 (en) 2019-03-19
CA2833296A1 (en) 2012-10-18
US20160362412A1 (en) 2016-12-15
HK1223371A1 (en) 2017-07-28
JP2016029092A (ja) 2016-03-03
RU2013150811A (ru) 2015-05-20
IL241846A0 (en) 2015-11-30
EP3018132B1 (en) 2017-12-13
CN105111210A (zh) 2015-12-02
AU2016277574B2 (en) 2018-04-19
JP6145491B2 (ja) 2017-06-14
US20160002249A1 (en) 2016-01-07
MX340442B (es) 2016-07-08
CO6862146A2 (es) 2014-02-10
PE20141124A1 (es) 2014-09-06
JP2014511876A (ja) 2014-05-19
AU2012242871A8 (en) 2013-11-21
LT3018132T (lt) 2018-03-26
CN105111210B (zh) 2018-10-09
NO2694640T3 (da) 2018-03-17

Similar Documents

Publication Publication Date Title
DK3018132T3 (da) Kondenserede imidazolderivater anvendt som ido-inhibitorer
EP3366678A1 (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
HK1223371B (en) Fused imidazole derivatives useful as ido inhibitors
HK1193822B (en) Fused imidazole derivatives useful as ido inhibitors
HK1213259B (en) Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization.